Podcasts

Drs Park and Grivas discuss key bladder cancer data presented at the 2026 ESMO Congress, highlighting the rapidly expanding treatment landscape.

Fadi Haddad, MD, discusses how to approach proper TKI adherence and selection in clinical practice for CML.

Nathan A. Boggs, MD, PhD, discusses the role allergists play in the diagnosis and management of systemic mastocytosis.

Drs Armstrong and Tawagi talk through a board exam preparation guide for the days leading up to the hematology and oncology certification exams.

Drs Juloori and Carbone explore how factors beyond PD-L1 expression, including histology, co-occurring genomic alterations, brain metastases, and patient fitness, can inform first-line regimen selection for patients with driver-negative metastatic NSCLC.

Drs Bazhenova and Patel explain why describing a tumor as “MET positive” is no longer specific enough in non–small cell lung cancer.

Drs Nunnery and Sammons discuss the management of HER2-positive metastatic breast cancer and brain metastases.

Drs Sen and Sands discuss lurbinectedin's place in the small cell lung cancer treatment paradigm.

Dr Hamilton discusses the FDA approval of tucatinib/trastuzumab/pertuzumab maintenance for unresectable, locally advanced HER2-positive breast cancer.

Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss potential avenues for at-home administration in myeloma.

Dr Secord discusses the emergence of B7-H4 as an attractive antibody-drug conjugate target in gynecologic cancers.

Drs Matulonis and Liu explore the rapidly expanding landscape of novel therapies for ovarian cancer, spanning the next generation of antibody-drug conjugates, resistance mechanisms, cell cycle targets, and emerging strategies for rare histologic subtypes.

Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss how on-body administration methods are affecting myeloma management.

Dr Chung discusses the development of atebimetinib in metastatic pancreatic cancer.

Nunnery and Moss discuss the often-overlooked gap in breast cancer survivorship care, beginning with Moss's personal story.

Ruben Mesa, MD, FACP, details the significance of the FDA approval of ropeginterferon alfa-2b for essential thrombocythemia.

Dr Reiss Binder discusses the significance of the FDA approval of daraxonrasib for pretreated metastatic pancreatic adenocarcinoma.

Dr Vogel highlights the rationale and growing evidence for sequential FGFR inhibition in FGFR2 fusion–positive cholangiocarcinoma.

Experts highlight the integration of subcutaneous therapies into the multiple myeloma treatment paradigm.

Drs Cooper and Choudhury discuss the evolving role of DLL3-targeting T-cell engagers in SCLC, with a focus on tarlatamab and how emerging trial data may reshape the current treatment paradigm across lines of therapy.

OncLive On Air®

Drs Aredo and Bleiberg reflect on the experiences and relationships that shaped their transitions from fellowship into their first faculty positions in thoracic oncology.

Tracy I. George, MD, discusses key factors for the diagnosis and management of systemic mastocytosis.

Elias Jabbour, MD, and Dennis Kim, MD, discuss recent data for olverembatininb and its place in CML management.

OncLive On Air®

Philip A. Philip, MD, discusses TTFields in pancreatic cancer and what phase 3 data has shown in locally advanced disease.

Drs Park and Kasi discuss the rise of neoadjuvant immunotherapy in CRC management, framing how this shift fits into the context of larger paradigm changes.

Nataliya Uboha, MD, PhD, discusses zanidatamab-based regimens, their recent approval, and the HERIZON-GEA-01 trial in gastric cancer.